[1] Huda S, Whittam D, Bhojak M, et al.Neuromyelitis optica spectrum disorders[J].Clin Med (Lond), 2019,19(2):169-176.
[2] Wallach A I, Tremblay M, Kister I.Advances in the treatment of neuromyelitis optica spectrum disorder[J].Neurol Clin, 2021,39(1):35-49.
[3] Dubey D, Kieseier B C, Hartung H P, et al.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates[J].Expert Rev Clin Immunol, 2015,11(1):93-108.
[4] Wu Y, Zhong L, Geng J.Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models[J].Mult Scler Relat Disord, 2019,27:412-418.
[5] Jarius S, Wildemann B, Paul F.Neuromyelitis optica: clinical features, immunopathogenesis and treatment[J].Clin Exp Immunol, 2014,176(2):149-164.
[6] Etemadifar M, Salari M, Mirmosayyeb O, et al.Efficacy and safety of rituximab in neuromyelitis optica: review of evidence[J].J Res Med Sci, 2017,22:18.
[7] Chihara N, Aranami T, Sato W, et al.Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica[J].Proc Natl Acad Sci U S A, 2011,108(9):3701-3706.
[8] Quan C, Yu H, Qiao J, et al.Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis[J].Mult Scler, 2013,19(3):289-298.
[9] Monteiro C, Fernandes G, Kasahara T M, et al.The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders[J].J Neuroimmunol, 2019,330:12-18.
[10] Fujihara K, Bennett J L, Seze J, et al.Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology[J].Neurol Neuroimmunol Neuroinflamm, 2020,7(5):241.
[11] Araki M.Blockade of IL-6 signaling in neuromyelitis optica[J].Neurochem Int, 2019,130:104315.
[12] Selmaj K, Selmaj I.Novel emerging treatments for NMOSD[J].Neurol Neurochir Pol, 2019,53(5):317-326.
[13] Cree B A, Lamb S, Morgan K, et al.An open label study of the effects of rituximab in neuromyelitis optica[J].Neurology, 2005,64(7):1270-1272.
[14] Damato V, Evoli A, Iorio R.Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis[J].JAMA Neurol, 2016,73(11):1342-1348.
[15] Gao F, Chai B, Gu C, et al.Effectiveness of rituximab in neuromyelitis optica: a meta-analysis[J].BMC Neurol, 2019,19(1):36.
[16] Tahara M, Oeda T, Okada K, et al.Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial[J].Lancet Neurol, 2020,19(4):298-306.
[17] Cree A C, Bennett J L, Kim H J, et al.Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial[J].Lancet, 2019,394(102):1352-1363.
[18] 朱 昆,于 倩,郭义明,等. 再次输注利妥昔单抗致严重不良反应1例[J].武警医学, 2018,29(11):1091-1093.
[19] Wolf A B, Ryerson L Z, Pandey K, et al.Rituximab-induced serum sickness in multiple sclerosis patients[J].Mult Scler Relat Disord, 2019,36:101402.
[20] Parrotta E, Ryerson L Z, Krupp L.It's not always an infection: pyoderma gangrenosum of the urogenital tract in two patients with multiple sclerosis treated with rituximab (1795)[J].Neurology, 2020,94(15 Supplement):1795.
[21] Ayzenberg I, Kleiter I, Schroder A, et al.Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy[J].JAMA Neurol, 2013,70(3):394-397.
[22] Serizawa K, Tomizawa S H, Miyake S, et al.Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders[J].Inflamm Regen, 2021,41(1):34.
[23] Zhang C, Zhang M, Qiu W, et al.Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial[J].Lancet Neurol, 2020,19(5):391-401.
[24] Lotan I, Charlson R W, Ryerson L Z, et al.Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders[J].Mult Scler Relat Disord, 2019,39:101920.
[25] Traboulsee A, Greenberg B M, Bennett J L, et al.Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial[J].Lancet Neurol, 2020,19(5):402-412.
[26] Yamamura T, Kleiter I, Fujihara K, et al.Trial of satralizumab in neuromyelitis optica spectrum disorder[J].N Engl J Med, 2019,381(22):2114-2124.
[27] Pittock S J, Lennon V A, McKeon A, et al.Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study[J].Lancet Neurol, 2013,12(6):554-562.
[28] Pittock S J, Berthele A, Fujihara K, et al.Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder[J].N Engl J Med, 2019,381(7):614-625.
[29] Maillart E, Renaldo F, Papeix C, et al.Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder[J].Neurol Neuroimmunol Neuroinflamm, 2020,7(3):566.
[30] Akaishi T, Nakashima I.Efficiency of antibody therapy in demyelinating diseases[J].Int Immunol, 2017,29(7):327-335.